[ Qiagen Suzhou Translational Medicine raises $25.73M in Series A ]
Qiagen Suzhou Translational Medicine has raised $25.73 million in Series A funding.
Founded in 2013, Qiagen Suzhou Translational Medicine provides services including biomarker R&D and development of companion diagnostics.
The company plans to build a GMP facility for R&D and production, expand its sales channels, and develop and commercialize its own companion diagnostics for immunotherapies and tumor-targeted candidates.
|Founder / CEO||Nick Zhang|
|Angel Medical Instrument|
|New Horizon Capital|
|Qiming Venture Partners|